PRINCETON, N.J.--(BUSINESS WIRE)--Agile Therapeutics, Inc., a pharmaceutical development company specializing in women’s healthcare products, today announced the Company has completed patient enrollment in its pivotal, Phase 3 NEW CHOICE Study of AG200-15, Agile’s lead contraceptive patch. Agile’s NEW CHOICE Study enrolled 1500 women at over 100 sites throughout the U.S. The study is comparing the efficacy and tolerability of AG200-15 to a low-dose, oral contraceptive. The NEW CHOICE Study completed enrollment two months ahead of schedule, enabling Agile to plan for an earlier submission of the New Drug Application (NDA) for AG200-15 to the U.S. Food and Drug Administration (FDA).
